On January 6, 2026, Apogee Therapeutics announced positive interim data from its Phase 1b trial of zumilokibart for asthma, showing a 60% reduction in a key biomarker after a single dose. The results highlight the drug's favorable safety profile and are significant for the company's future milstones in 2026.